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Metabolomics and systems
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Douglas B. Kell and Royston Goodacre
School of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK
Metabolism represents the ‘sharp end’ of systems biology, because changes in metabolite concentrations
are necessarily amplified relative to changes in the transcriptome, proteome and enzyme activities,
which can be modulated by drugs. To understand such behaviour, we therefore need (and increasingly
have) reliable consensus (community) models of the human metabolic network that include the
important transporters. Small molecule ‘drug’ transporters are in fact metabolite transporters, because
drugs bear structural similarities to metabolites known from the network reconstructions and from
measurements of the metabolome. Recon2 represents the present state-of-the-art human metabolic
network reconstruction; it can predict inter alia: (i) the effects of inborn errors of metabolism; (ii) which
metabolites are exometabolites, and (iii) how metabolism varies between tissues and cellular
compartments. However, even these qualitative network models are not yet complete. As our
understanding improves so do we recognise more clearly the need for a systems (poly)pharmacology.Introduction – a systems biology approach to drug
discovery
It is clearly not news that the productivity of the pharmaceutical
industry has declined significantly during recent years [1–14]
following an ‘inverse Moore’s Law’, Eroom’s Law [11], or that
many commentators, for example, see [7,8,14–47], consider that
the main cause of this is because of an excessive focus on indivi-
dual molecular target discovery rather than a more sensible strat-
egy based on a systems-level approach (Fig. 1).
Arguably the two chief hallmarks of the systems biology
approach are: (i) that we seek to make mathematical models of
our systems iteratively or in parallel with well-designed ‘wet’
experiments, and (ii) that we do not necessarily start with a
hypothesis [48,49] but measure as many things as possible (the
‘omes) and let the data tell us the hypothesis that best fits and
describes them. Although metabolism was once seen as something
of a Cinderella subject [50,51], there are fundamental reasons to do
with the organisation of biochemical networks as to why theCorresponding author. Kell, D.B. (dbk@manchester.ac.uk)
1359-6446/06  2014 The Authors. Published by Elsevier B.V. http://dx.doi.org/1Open access under CC BY license.metabol(om)ic level – now in fact seen as the ‘apogee’ of the
‘omics trilogy [52] – is indeed likely to be far more discriminating
than are changes in the transcriptome or proteome. The next two
subsections deal with these points and Fig. 2 summarises the paper
in the form of a Mind Map.
Modelling biochemical networks – why we do so
As set out previously [19,53–55], and as can be seen in every systems
biology textbook [56–58], there are at least four types of reasons as to
why one would wish to model a biochemical network:
 Assessing whether the model is accurate, in the sense that it
reflects – or can be made to reflect – known experimental facts.
 Establishing what changes in the model would improve the
consistency of its behaviour with experimental observations
and improved predictability, such as with respect to metabolite
concentrations or fluxes.
 Analyzing the model, typically by some form of sensitivity
analysis [59], to understand which parts of the system contribute
most to some desired functional properties of interest.
 Hypothesis generation and testing, enabling one to analyse
rapidly the effects of manipulating experimental conditions in
the model without having to perform complex and costly
experiments (or to restrict the number that are performed).0.1016/j.drudis.2013.07.014 www.drugdiscoverytoday.com 171
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FIGURE 1
The change in drug discovery strategy from ‘classical’ function-first
approaches (in which the assay of drug function was at the tissue or organism
level), with mechanistic studies potentially coming later, to more-recent
target-based approaches where initial assays usually involve assessing the
interactions of drugs with specified (and often cloned, recombinant) proteins
in vitro. In the latter cases, effects in vivo are assessed later, with concomitantly
high levels of attrition.
R
eview
s
P
O
S
T
S
C
R
E
E
NIn particular, it is normally considerably cheaper to perform
studies of metabolic networks in silico before trying a smaller
number of possibilities experimentally; indeed for combinatorial
reasons it is often the only approach possible [60,61]. Although
our focus here is on drug discovery, similar principles apply to the
modification of biochemical networks for purposes of ‘industrial’
or ‘white’ biotechnology [62–68].
Why we choose to model metabolic networks more than tran-
scriptomic or proteomic networks comes from the recognition –
made particularly clear by workers in the field of metabolic control
analysis [69–77] – that, although changes in the activities of
individual enzymes tend to have rather small effects on metabolicPutting it together:
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FIGURE 2
A Mind Map summarising this paper.
172 www.drugdiscoverytoday.comfluxes, they can and do have very large effects on metabolite
concentrations (i.e. the metabolome) [78–81]. Thus, the metabo-
lome serves to amplify possibly immeasurably small changes in the
transcriptome and the proteome, even when derived from minor
changes in the genome [82–84]. Note here that in metabolic
networks the parameters are typically the starting enzyme con-
centrations and rate constants, whereas the system variables are
the metabolic fluxes and concentrations, and that as in all systems
the parameters control the variables and not vice versa. This
recognition that small changes in network parameters can cause
large changes in metabolite concentrations has led to the concept
of metabolites as biomarkers for diseases. Although an important
topic, it has been reviewed multiple times recently [85–105] and,
for reasons of space and the rarity of their assessment via network
biology, disease biomarkers are not our focus here.
Modelling biochemical networks – how we do so
Although one could seek to understand the time-dependent spatial
distribution of signalling and metabolic substances within indivi-
dual cellular compartments [106,107] and while spatially discrimi-
nating analytical methods such as Raman spectroscopy [108] and
mass spectrometry [109–113] do exist for the analysis of drugs in situ,
the commonest type of modelling, as in the spread of substances in
ecosystems [114], assumes ‘fully mixed’ compartments and thus
‘pools’ of metabolites, cf. [115,116]. Although an approximation,
this ‘bulk’ modelling will be necessary for complex ecosystems such
as humans where, in addition to the need for tissue- and cell-specific
models, microbial communities inhabit this superorganism and the
gut serves as a source for nutrients courtesy of these symbionts [117].
The gut microflora contain some 1013–1014 bacteria (over 1000
bacterial species, each with their own unique metabolic network)
that allow metabolite transformation and cross-feeding within the
prokaryotic group and to our gut epithelia; it is also noteworthy
that, although antibiotics have an obvious effect here, other
human-targeted pharmaceuticals will also undergo microbial drugSystem biology
approach to drug
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biochemical
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FIGURE 3
Two views of the role of solute carriers and other transporters in cellular drug
uptake. (a) A more traditional view in which all so-called ‘passive’drug uptake
occurs through any unperturbed bilayer portion of membrane that might be
present. (b) A view in which the overwhelming fraction of drug is taken up via
solute transporters or other carriers that are normally used for the uptake of
intermediary metabolites. Noting that the protein:lipid ratio of
biomembranes is typically 3:1 to 1:1 and that proteins vary in mass and
density [440,441] (a typical density is 1.37 g/ml [441]) as does their extension,
for example, see [442], normal to the ca. 4.5 nm [443] lipid bilayer region, the
figure attempts to portray a section of a membrane with realistic or typical
sizes [441] and amounts of proteins and lipids. Typical protein areas when
viewed normal to the membrane are 30% [444,445], membranes are rather
more ‘mosaic’ than ‘fluid’ [442,446] and there is some evidence that there
might be no genuinely ‘free’ bulk lipids (typical phospholipid masses are
750 Da) in biomembranes that are uninfluenced by proteins [447]. Also
shown is a typical drug: atorvastatin (LipitorW) – with a molecular mass of
558.64 Da – for size comparison purposes. If proteins are modelled as
cylinders, a cylinder with a diameter of 3.6 nm and a length of 6 nm has a
molecular mass of ca. 50 kDa. Note of course that in a ‘static’ picture we
cannot show the dynamics of either phospholipid chains (e.g. [448]) or lipid
(e.g. [449–451]) or protein diffusion (e.g. [452,453]).
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Overall, metabolites can be seen as the nodes of (mathematical)
graphs [119] – familiar as the conventional biochemical networks of
laboratory posters [120], now available digitally – for which the edges
reflect enzymes catalysing interconversions of biochemical sub-
stances (as well as transporters, see below). Modelling such networks
typically involves a four-stage approach [19,20,53,54,121].
In the first, qualitative stage we list all the reactions that are
known to occur in the organism or system of interest. It is
increasingly possible to automate this [122–126], including
through the use of the techniques of text mining [127–131]. A
second stage, also qualitative, adds known effectors (activators and
inhibitors). The third and fourth stages are more quantitative in
character and involve addition of the known, or surrogate [132–
134], kinetic rate equations and the values of their parameters
(such as Kcat and Km). Given such information, it is then possible to
provide a stochastic [135,136] or ordinary [137] differential equa-
tion model of the entire metabolic network of interest, typically
encoded in the Systems Biology Markup Language (SBML; http://
sbml.org/) [138], using one of the many suites of software avail-
able, for example Cell Designer [139], COPASI [140–143] or Cytos-
cape [144,145].
Topology and stoichiometry of metabolic networks as
major constraints on fluxes
Given their topology, which admits a wide range of parameters for
delivering the same output effects and thereby reflects biological
robustness [146–149], metabolic networks have two especially
important constraints that assist their accurate modelling
[58,77,150,151]: (i) the conservation of mass and charge, and
(ii) stoichiometric and thermodynamic constraints [152]. These
are tighter constraints than apply to signalling networks.
New developments in modelling the human metabolic
network
Since 2007 [153,154], several groups have been developing
improved but nonidentical [155] models of the human metabolic
network at a generalised level [156–159] and in tissue-specific
[160–168] forms. Following a similar community-driven [169]
strategy in Saccharomyces cerevisiae [121], surprisingly similar to
humans [170,171], and in Salmonella typhimurium [172], we focus
in particular on a recent consensus paper [159] that provides a
highly curated and semantically annotated [55,173,174] model of
the human metabolic network, termed Recon2 (http://humanme-
tabolism.org/). In this work [159], a substantial number of the
major groups active in this area came together to provide a care-
fully and manually constructed/curated network, consisting of
some 1789 enzyme-encoding genes, 7440 reactions and 2626
unique metabolites distributed over eight cellular compartments.
Note, however, that a variety of dead-end metabolites and blocked
reactions remain (essentially orphans and widows). Nevertheless,
Recon2 was able to account for some 235 inborn errors of meta-
bolism, see also [175], as well as a huge variety of metabolic ‘tasks’
(defined as a non-zero flux through a reaction or through a path-
way leading to the production of a metabolite Q from a metabolite
P). In addition, filtering based on expression profiling allowed the
constrution of 65 cell-type-specific models. Excreted or exometa-
bolites [176–182] are a particularly interesting set of metabolites,and Recon2 could predict successfully a substantial fraction of
those [159].
Role of transporters in metabolic fluxes
The uptake and excretion of metabolites between cells and their
macrocompartments requires specific transporters and in the
order of one third of ‘metabolic’ enzymes [153,154], and indeed
of membrane proteins [183,184], are in fact transporters or equiva-
lent. What is of particular interest (to drug discovery), based on
their structural similarities [185–188], is the increasing recognition
[149,189–199] (Fig. 3) that pharmaceutical drugs also get into and
out of cells by ‘hitchhiking’ on such transporters, and not – to any
significant extent – by passing through phospholipid bilayer por-
tions of cellular membranes. This makes drug discovery even more
a problem of systems biology than of biophysics.www.drugdiscoverytoday.com 173
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Workflow for expression-profile-
constrained metabolic flux estimation
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FIGURE 4
The steps in a workflow that uses constraints based on (i) metabolic network
stoichiometry and chemical reaction properties (both encoded in the model)
plus, and (ii) absolute (RNA-Seq) transcript expression profiles to enable the
accurate modelling of pathway and exometabolite fluxes. The full strategy
and results are described in [297].
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To illustrate the ‘unfinished’ nature even of Recon2, which con-
centrates on the metabolites created via enzymes encoded in the
human genome, and leaving aside the more exotic metabolites of
drugs and foodstuffs and the ‘secondary’ [200] metabolites of
microorganisms, there are several examples of interesting ‘new’
(i.e. more or less recently recognised) human metabolites or roles
thereof that are worth highlighting, often from studies seeking
biomarkers of various diseases – for caveats of biomarker discovery,
which is not a topic that we are covering here, and the need for
appropriate experimental design, see [201]. Examples include N-
acetyltaurine [202], 27-nor-5b-cholestane-3,7,12,24,25 pentol glu-
curonide [203], the cytidine-5-monophosphate:pentadecanoic
acid ratio [204], desmosterol [205], F2-isoprostanes [206–208],
galactose-6-phosphate [209], globotriaosylsphingosines (lyso-
Gb3) [210,211], cyclic GMP-AMP [212,213], hexacosanedioic acid
[214], L-homoarginine [94,215,216], D-2-hydroxyglutarate
[217,218], 3-(4-hydroxy-phenyl)propionic acid [219], 3-methyl
histidine [220], 3-indoxyl sulphate [221], N-methyl nicotinamide
[188,222], neopterin [223–225], ophthalmic acid [226], O-phos-
phoethanolamine [227], 2-piperidinone [228], pseudouridine
[229], 4-pyridone-3-carboxamide-1-b-D-ribonucleoside tripho-
sphate [230], Se-methylselenoneine [231], a mammalian sidero-
phore [232–234], sphinganine [235], sphingosine-1-phosphate
[236], succinyltaurine [237] and 3-ureido-propionate [238], as well
as a variety of metabolites coming from or modulated by the
human microbiome [100,117,239–244]. Other classes of metabo-
lites not well represented in Recon2 are oxidised molecules [245]
such as those caused by nonenzymatic reaction of metabolites
with free radicals such as the hydroxyl radical generated by unli-
ganded iron [246–250]. There is also significant interest in using
methods of determining small molecules such as those in the
metabolome (inter alia) for assessing the ‘exposome’ [251–255],
in other words all the potentially polluting agents to which an
individual has been exposed [256].
Recently discovered effects of metabolites on enzymes
Another combinatorial problem [61] reflects the fact that in
molecular enzymology it is not normally realistic to assess every
possible metabolite to determine whether it is an effector (i.e.
activator or inhibitor) of the enzyme under study. Typical pro-
teins are highly promiscuous [199,257,258] and there is increas-
ing evidence for the comparative promiscuity of metabolites
[259–261] and pharmaceutical drugs [26,39,199,262–271]. Cer-
tainly the contribution of individual small effects of multiple
parameter changes can have substantial effects on the potential
flux through an overall pathway [272], which makes ‘bottom up’
modelling an inexact science [273]. Even merely mimicking the in
vivo (in Escherichia coli) concentrations of K+, Na+, Mg2+, phos-
phate, glutamate, sulphate and Cl significantly modulated the
activities of several enzymes tested relative to the ‘usual’ assay
conditions [274]. Consequently, we need to be alive to the pos-
sibility of many (potentially major) interactions of which we are
as yet ignorant. One class of example relates to the effects of the
very widespread [275] post-translational modification on meta-
bolic enzyme activities. Other recent examples include ‘unex-
pected’ effects of b-hydroxybutyrate on histone deacetylase [276],
of serine on pyruvate kinase [277], of threonine on histone174 www.drugdiscoverytoday.commethylation and stem cell fate [278], of trehalose-6-phosphate
on plant flowering time [279] and of lauroyl carnitine on macro-
phages [280].
In addition, some metabolites are known to affect drug trans-
portation into cells; a well known example of this occurs with
grapefruit [281–285], which contains naringin [286] that in
humans is metabolised to naringenin [287]. As well as interacting
with transporters to change absorption of drugs across the gut
which modulates their bioavailability, these phytochemicals also
inhibit various P450 activities and this can lead to prolonged and
elevated drug levels; indeed several deaths have been linked to the
consumption of grapefruit altering the concentration and/or bioa-
vailability of a variety of pharmaceuticals.
Constraint-based modelling of metabolic fluxes
Armed with the metabolic network models, it is possible to predict
metabolic fluxes directly. This can be done in a ‘forward’ direction
(as above; given the network, starting concentrations of enzymes
and metabolites, and rate equations one can then predict the
fluxes), in an ‘inverse’ direction (given the fluxes and concentra-
tions one can try to predict the enzyme concentrations and kinetic
parameters that would account for them [288–296]) or iteratively,
using both kinds of knowledge. Historically, it has been common
to use a ‘biomass’ term as a kind of dumping ground for uncertain
fluxes. However, a recent and important discovery [297] (Fig. 4) is
that a single transcriptome experiment, serving as a surrogate for
fluxes through individual steps, provides a huge constraint on
possible models, and predicts in a numerically tractable way and
with much improved accuracy the fluxes to exometabolites with-
out the need for such a variable ‘biomass’ term. Other recent and
related strategies that exploit modern advances in ‘omics and
network biology to limit the search space in constraint-based
metabolic modelling include references [137,151,298–306].
Improvements in methods for measuring metabolites
Since its modern beginnings [78,307–310], metabolomics is sig-
nificantly seen as an analytical science, in that it depends on our
Drug Discovery Today  Volume 19, Number 2  February 2014 REVIEWS
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centrations of a multitude of chemically diverse metabolites. As
such it is worth highlighting a few recent papers that have
improved these abilities – mainly via improvements in chromato-
graphy–mass spectrometry [81,84,102,311–322] in terms of
increased coverage [255,323–329], metabolite identification
[316,330–341], flux and pathway analysis [65,301,342–354],
long-term robustness [355,356], sensitivity [357–359], precision
[315,358,360–364], discrimination [228,287,365–367], among
others. It is clear from the above that many analytical approaches
are used to measure metabolites and, in addition to the chemical
diversity of metabolites, each metabolomics platform typically has
different levels of sensitivity. NMR spectroscopy measures small
molecules typically in the mM to high mM range, gas chromato-
graphy–mass spectrometry (GC–MS) detects metabolites in the
range from mM to mM and liquid chromatography (LC)–MS sig-
nificantly lower in the nM to mM levels [368]. Sample preparation is
also an important and sometimes overlooked component of the
analysis [369,370], and can be based on predictable chemistry
[371].
Novel methods of data analysis also remain very important
[372,373], and some examples of these include metabolomics pipe-
lines [374,375], peak alignment [376] and calibration transfer [377–
379], between-metabolite relationships [380], metabolite time series
comparisons [381], cross correlations [382], multiblock principal
components [383] and partial least squares [384] analysis, metabo-
lome databases [340,385–396], methods for mode-of-actiondiscovery [365,397–401], data management [402,403] and stan-
dards [404,405], and statistical robustness [406,407].
Concluding remarks – the role of metabolomics in
systems pharmacology
What is becoming increasingly clear, as we recognise that to
understand living organisms in health and disease we must treat
them as systems [96,149], is that we must bring together our
knowledge of the topologies and kinetics of metabolic networks
with our knowledge of the metabolite concentrations (i.e. meta-
bolomes) and fluxes. Because of the huge constraints imposed on
metabolism by reaction stoichiometries, mass conservation and
thermodynamics, comparatively few well-chosen ‘omics measure-
ments might be needed to do this reliably [297] (Fig. 4). Indeed, a
similar approach exploiting constraints has come to the fore in de
novo protein folding and interaction studies [408–412].
What this leads us to in drug discovery is the need to develop
and exploit a ‘systems pharmacology’ [18,30,32,40,45–
47,149,156,413–429] where multiple binding targets are chosen
purposely and simultaneously. Along with other measures such as
phenotypic screening [8,430,431], and the integrating of the full
suite of e-science approaches [44,131,405,432–439], one can
anticipate considerable improvements in the rate of discovery
of safe and effective drugs.
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